This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer.
Comella, P., Lorusso, V., Maiorino, L., Casaretti, R., Cannone, M., Massidda, B., et al. (2009). Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 64(5), 893-899 [10.1007/s00280-009-0938-4].
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group
ROSELLI, MARIO;
2009-10-01
Abstract
This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Oxaliplatin, irinotecan, and fluorouracil folinic acid in advanced gastric cancer.pdf
accesso aperto
Dimensione
273.7 kB
Formato
Adobe PDF
|
273.7 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
